Encompass Health Is Up 110%-But Fair Value Says the Run May Still Be Right

Near the highs, but not obviously near fair value

The market is acting like Encompass Health has already had its move. After an 83.0% return over the past 5 years, many investors assume the easy upside is gone. But price strength and fair value are not the same thing: a stock can be close to its highs and still not be close to a cash-flow-based fair value.

Right now, EHC is trading around 20.32x earnings. That is not, on its own, an obvious bubble multiple. It suggests the market is paying more for the stock than it did in a low-by-earnings regime, but not necessarily a full scarcity price for a leader in post-acute care.

Why the 52-week high can mislead

The shares are -13.35% from its 52-week high of $127.99. That invites anchoring. Traders start thinking, "It has already rallied so much," which can lead to premature profit-taking.

Yet the valuation gap still looks meaningful. The cash-flow model in the source material still points to about $175.72 per share. That does not guarantee upside, but it does show why a stock can remain interesting even after a major run.

Why the Oct. 28 report matters

The near-term decision point is the next earnings release. Encompass Health reports on Oct. 28, 2026. If management continues to sound confident in execution, the market may keep treating the stock as a rerating story rather than a one-time rebound.

The case for buying through a big run

The rally has a business case, not just a momentum case

A stock can keep climbing after a big move if buyers believe it can produce more cash than the market is currently willing to pay for. That is part of the setup here: Encompass Health still screens as undervalued in 5 of 6 areas even after a strong multiyear run. Momentum may be helping the stock, but the underlying reason investors are staying interested is that the valuation checks still look constructive.

Encompass Health is a large operating platform

Post-acute rehab is a volume- and efficiency-driven business, and scale matters. On the latest figures available, Encompass Health has Revenue (TTM) of $6.21B and EBITDA (TTM) of $1.46B. Those are substantial numbers for a company focused on inpatient rehabilitation and related post-acute care.

That matters because a larger platform may handle case-mix shifts, utilization changes, and cost pressure better than smaller operators. When demand is healthy, scale should make cash flow more resilient.

The main risk is reimbursement, not demand

The bear case is probably not that rehab demand disappears. It is that payment rules reduce how much of that demand can become shareholder value. The evidence base is clear that any shift in healthcare policy or reimbursement may limit how much value those cash flows ultimately create for shareholders.

That is the key tension. Bulls can overstate the story by focusing only on demand and operating momentum. Bears can overstate policy risk and miss a company that is still large enough to keep improving through scale and execution. A balanced read is simpler: the business can keep getting better, but the equity case remains more sensitive to reimbursement than many investors want to admit.

What to watch before the report

Price action is constructive, but it still looks mid-range rather than euphoric. EHC is +19.54% from its 52-week low and -13.35% from its 52-week high of $127.99. That suggests the market is getting more constructive, not that investors are blindly chasing the stock at any price.

So the Oct. 28 report matters less as a binary headline event and more as a stress test for the rerating thesis. Strong commentary on demand, margins, and reimbursement exposure would support the idea that the move higher still has business support. Weakness on payment pressure or execution would make the 110% run look harder to defend.